Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An olfactory neuroblastoma arising in the paranasal sinus.
Biomarker and diagnostic research for olfactory neuroblastoma has been reported in the published literature.
11 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE4, 4 PHASE2, 3 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06814496](https://clinicaltrials.gov/study/NCT06814496) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
PHASE1 |
University of Arizona |
RECRUITING |
[NCT04755205](https://clinicaltrials.gov/study/NCT04755205) | A Natural History Study of Children and Adults With Olfactory Neuroblastoma | — | National Cancer Institute (NCI) | RECRUITING |
[NCT06255210](https://clinicaltrials.gov/study/NCT06255210) | Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) | PHASE2 | Hongmeng Yu | RECRUITING |
[NCT06176989](https://clinicaltrials.gov/study/NCT06176989) | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT07100704](https://clinicaltrials.gov/study/NCT07100704) | Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab | PHASE2 | National Cancer Center Hospital East | RECRUITING |
135 publications have been identified in PubMed for olfactory neuroblastoma. Research spans Case Report / Case Series (25%), Review / Meta-Analysis (23%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 | 25% |
Research summaries | 31 | 23% |
Clinical study results | 17 | 13% |
Laboratory research | 16 | 12% |
Disease patterns and progression | 16 | 12% |
Testing and diagnosis research | 15 | 11% |
New treatment approaches | 6 | 4% |
Bayraktar FGİ (2026). [PMID: 41190732](https://pubmed.ncbi.nlm.nih.gov/41190732/). *The Laryngoscope*. [Review / Meta-Analysis]
Tang A (2026). [PMID: 41165699](https://pubmed.ncbi.nlm.nih.gov/41165699/). *JAMA otolaryngology-- head & neck surgery*. [Gene Therapy / Novel Therapeutics]
Zhong CY (2026). [PMID: 41735419](https://pubmed.ncbi.nlm.nih.gov/41735419/). *Sci Rep*. [Gene Therapy / Novel Therapeutics]
Patel EJ (2026). [PMID: 41808975](https://pubmed.ncbi.nlm.nih.gov/41808975/). *J Neurol Surg B Skull Base*. [Diagnostic / Biomarker]
Hellquist H (2026). [PMID: 42053816](https://pubmed.ncbi.nlm.nih.gov/42053816/). *Virchows Arch*. [Review / Meta-Analysis]
Liao HR (2026). [PMID: 41684991](https://pubmed.ncbi.nlm.nih.gov/41684991/). *Cureus*. [Case Report / Case Series]
Olson E (2026). [PMID: 41503426](https://pubmed.ncbi.nlm.nih.gov/41503426/). *J Neurol Surg B Skull Base*. [Case Report / Case Series]
Farkas M (2026). [PMID: 41803273](https://pubmed.ncbi.nlm.nih.gov/41803273/). *Virchows Archiv : an international journal of pathology*. [Case Report / Case Series]
Hsia B (2026). [PMID: 42095028](https://pubmed.ncbi.nlm.nih.gov/42095028/). *J Neurol Surg B Skull Base*. [Basic Science / Preclinical]
Wu L (2026). [PMID: 41628435](https://pubmed.ncbi.nlm.nih.gov/41628435/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
AI-curated news mentioning olfactory neuroblastoma
Updated May 28, 2026
A recent study published in PubMed examines clinical outcomes and failure patterns following postoperative intensity-modulated radiation therapy (IMRT) for olfactory neuroblastoma. The findings highlight late cervical nodal relapse as a significant concern in patient management.
A recent study published in PubMed examines outcomes following en bloc resection of olfactory neuroblastoma, providing insights into surgical efficacy and patient prognosis. This research contributes to the understanding of treatment options for this rare cancer.
A recent study published in PubMed explores the detection of DNA viruses in olfactory neuroblastomas using targeted enrichment next-generation sequencing. This research could enhance understanding of the viral involvement in this rare tumor type.